PL4392550T3 - Ukierunkowanie na komórki e. coli - Google Patents

Ukierunkowanie na komórki e. coli

Info

Publication number
PL4392550T3
PL4392550T3 PL23738642.0T PL23738642T PL4392550T3 PL 4392550 T3 PL4392550 T3 PL 4392550T3 PL 23738642 T PL23738642 T PL 23738642T PL 4392550 T3 PL4392550 T3 PL 4392550T3
Authority
PL
Poland
Prior art keywords
targeting
coli cells
coli
cells
Prior art date
Application number
PL23738642.0T
Other languages
English (en)
Inventor
Jakob KRAUSE HAABER
Szabolcs SEMSEY
Mette GROVE
Birgitte DAMHOLT
Dziuginta JASINSKYTE
Yilmaz Emre GENÇAY
Original Assignee
Snipr Biome Aps.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2209518.6A external-priority patent/GB202209518D0/en
Priority claimed from GBGB2303242.8A external-priority patent/GB202303242D0/en
Application filed by Snipr Biome Aps. filed Critical Snipr Biome Aps.
Publication of PL4392550T3 publication Critical patent/PL4392550T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL23738642.0T 2022-06-29 2023-06-29 Ukierunkowanie na komórki e. coli PL4392550T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2209518.6A GB202209518D0 (en) 2022-06-29 2022-06-29 Treating & preventing E coli infections
GBGB2303242.8A GB202303242D0 (en) 2023-03-06 2023-03-06 Targeting E coli cells
PCT/EP2023/067906 WO2024003301A1 (en) 2022-06-29 2023-06-29 Targeting e coli cells

Publications (1)

Publication Number Publication Date
PL4392550T3 true PL4392550T3 (pl) 2025-10-06

Family

ID=87158512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23738642.0T PL4392550T3 (pl) 2022-06-29 2023-06-29 Ukierunkowanie na komórki e. coli

Country Status (11)

Country Link
US (1) US20250205293A1 (pl)
EP (2) EP4660305A3 (pl)
JP (1) JP2025525414A (pl)
KR (1) KR20250031203A (pl)
CN (1) CN120035659A (pl)
AU (1) AU2023301441A1 (pl)
CA (1) CA3259681A1 (pl)
ES (1) ES3039826T3 (pl)
IL (1) IL317786A (pl)
PL (1) PL4392550T3 (pl)
WO (1) WO2024003301A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2024184403A2 (en) * 2023-03-06 2024-09-12 Snipr Biome Aps Targeting cells in stressed growing conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020044922A1 (en) 1996-02-06 2002-04-18 Sven Mardh Recombinant phages
JP2002543816A (ja) 1999-05-13 2002-12-24 エクスポネンシャル バイオセラピーズ，アイエヌシー． バンコマイシン耐性腸球菌株に感染した患者を救済するために有用なバクテリオファージ株
US20020001590A1 (en) 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
AU2001263408A1 (en) 2000-05-23 2001-12-03 The Rockefeller University C1 bacteriophage lytic system
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
ATE305793T1 (de) 2000-07-25 2005-10-15 Us Gov Health & Human Serv Bakteriophage mit breitem wirtspektrum
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
DE18305781T1 (de) * 2018-06-20 2020-09-17 Eligo Bioscience Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon
WO2021092254A1 (en) * 2019-11-06 2021-05-14 Locus Biosciences, Inc. Phage compositions comprising crispr-cas systems and methods of use thereof

Also Published As

Publication number Publication date
EP4392550A1 (en) 2024-07-03
EP4392550B8 (en) 2025-10-01
CA3259681A1 (en) 2024-01-04
IL317786A (en) 2025-02-01
EP4392550C0 (en) 2025-08-20
ES3039826T3 (en) 2025-10-24
EP4392550B1 (en) 2025-08-20
EP4660305A2 (en) 2025-12-10
JP2025525414A (ja) 2025-08-05
KR20250031203A (ko) 2025-03-06
AU2023301441A1 (en) 2025-02-13
CN120035659A (zh) 2025-05-23
US20250205293A1 (en) 2025-06-26
WO2024003301A1 (en) 2024-01-04
EP4660305A3 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
IL317786A (en) Targeting E. coli cells
CA196630S (en) Electrode array
PL4384223T3 (pl) Ukierunkowujące cytotoksyczność chimery dla komórek eksprymujących ccr2
EP3740242B8 (en) Langerin+ cell targeting
AU2022205653A9 (en) T cell therapy
IL321083A (en) Advanced RNA Targeting (ARNATAR)
GB202303242D0 (en) Targeting E coli cells
GB202209920D0 (en) Cell
GB202105278D0 (en) Cell therapy
CA3285192A1 (en) Technologies targeting cell states
HK40108044A (en) Cytotoxicity targeting chimeras for ccr2-expressing cells
GB202303076D0 (en) Cell penetrating agent targeting IL-1R
GB202007073D0 (en) Cells for cancer targeting
GB202007072D0 (en) Cells for cancer targeting
GB2618580B (en) Electrode assembly
CA3299202A1 (en) Cell wall hydrolases targeting c. acnes
AU2024299926A1 (en) Cell wall hydrolases targeting c. acnes
GB202303473D0 (en) Targeting peptide
GB202005263D0 (en) Cell penetrating agent targeting IL-1R
GB202203339D0 (en) Targeting peptide
GB202019006D0 (en) GFR targeting compounds
GB202314218D0 (en) Cell therapy
GB202213556D0 (en) Armour
GB202215623D0 (en) Electrodes
CA3273709A1 (en) Targeting sortilin